STOCK TITAN
  1. Home
  2. Sec-filings
  3. BSX
  4. [Form 4] BOSTON SCIENTIFIC CORP Insider Trading Activity

Boston Scientific (NYSE: BSX) director receives deferred stock unit awards as equity pay

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Smith Cathy R reported acquisition or exercise transactions in this Form 4 filing.

Boston Scientific director Cathy R. Smith received equity compensation in the form of deferred stock units. On 2026-05-07, she was granted 2,209 deferred stock units tied to common stock as an annual equity award valued at $215,000, plus 3,800 additional deferred stock units granted in lieu of $125,000 of yearly cash compensation.

Each deferred stock unit represents a commitment to issue one share of Boston Scientific common stock. Both awards vest in full at the next annual meeting of stockholders, with shares delivered only after she leaves the Board under the Non-Employee Director Deferred Compensation Plan. Following these grants, reported deferred stock unit balances in the respective plans were 6,888 and 4,679 units.

Positive

  • None.

Negative

  • None.
Insider Smith Cathy R
Role null
Type Security Shares Price Value
Grant/Award Deferred Stock Units 3,800 $0.00 --
Grant/Award Deferred Stock Units 2,209 $0.00 --
Holdings After Transaction: Deferred Stock Units — 4,679 shares (Direct, null)
Footnotes (1)
  1. Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant. Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Deferred stock units were granted in lieu of 100% yearly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $125,000 (representing 100% of the amount of the non-employee director compensation program's cash retainer) divided by the closing price of the common stock on the date of grant.
Deferred stock unit grant 1 2,209 units Annual equity award on 2026-05-07
Deferred stock unit grant 1 value $215,000 Converted to units at closing price on grant date
Deferred stock unit grant 2 3,800 units Granted in lieu of cash compensation on 2026-05-07
Deferred stock unit grant 2 value $125,000 Equals 100% of annual cash retainer, converted at closing price
Units held after grant 1 6,888 units Deferred stock unit balance after 2,209-unit award
Units held after grant 2 4,679 units Deferred stock unit balance after 3,800-unit award
Deferred Stock Units financial
"Each deferred stock unit represents the Company's commitment to issue one share"
Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.
annual equity award financial
"Annual equity award in the form of deferred stock units vesting in full"
Non-Employee Director Deferred Compensation Plan financial
"in accordance with the Company's Non-Employee Director Deferred Compensation Plan"
cash retainer financial
"representing 100% of the amount of the non-employee director compensation program's cash retainer"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Smith Cathy R
(Last)(First)(Middle)
300 BOSTON SCIENTIFIC WAY
(Street)
MARLBOROUGH MASSACHUSETTS 01752-1234
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Deferred Stock Units(1)05/07/2026A3,800(2) (3) (3)Common Stock3,800$0.00004,679D
Deferred Stock Units(1)05/07/2026A2,209(4) (4) (4)Common Stock2,209$0.00006,888D
Explanation of Responses:
1. Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
2. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.
3. Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan.
4. Deferred stock units were granted in lieu of 100% yearly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $125,000 (representing 100% of the amount of the non-employee director compensation program's cash retainer) divided by the closing price of the common stock on the date of grant.
/s/ Susan Thompson, Attorney-in-Fact05/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Boston Scientific (BSX) director Cathy R. Smith report in this Form 4?

She reported two equity compensation grants in deferred stock units. One grant covered 2,209 units as an annual equity award and another 3,800 units in lieu of cash fees, both tied to Boston Scientific common stock and vesting at the next annual meeting.

How many deferred stock units did BSX director Cathy R. Smith receive?

She received 2,209 deferred stock units in one grant and 3,800 units in another. Each unit represents a future share of Boston Scientific common stock, subject to vesting and later issuance after her Board service ends under the company’s deferred compensation plan.

What is the dollar value of Cathy R. Smith’s Boston Scientific (BSX) equity awards?

One award reflects a value of $215,000 divided by the closing stock price on the grant date. The second reflects $125,000, equal to 100% of the non-employee director cash retainer, also converted into deferred stock units at that day’s closing price.

When do Cathy R. Smith’s Boston Scientific (BSX) deferred stock units vest and pay out?

Both deferred stock unit grants vest in full at the next annual meeting of stockholders. Vested shares of Boston Scientific common stock will be issued only after her separation from Board service, following the Non-Employee Director Deferred Compensation Plan terms.

Are Cathy R. Smith’s Boston Scientific (BSX) grants open-market purchases or sales?

No, they are compensation-related grants coded as awards, not market trades. The Form 4 shows acquisitions of deferred stock units at a price of $0.0000 per unit, reflecting director compensation rather than buying or selling shares in the open market.

How many deferred stock units does Cathy R. Smith hold after these BSX grants?

After the 2,209-unit grant, her reported balance in that deferred stock unit line is 6,888 units. After the separate 3,800-unit grant, her balance in that line is 4,679 units, representing two sets of deferred compensation positions tied to Boston Scientific common stock.